Brexanolone as adjunctive therapy in super-refractory status epilepticus.

Eric S RosenthalJan ClaassenMark S WainwrightAatif M HusainHenrikas VaitkeviciusShane RainesEthan HoffmannHelen ColquhounJames J DohertyStephen J Kanes

Published in: Annals of neurology (2017)

In an open-label cohort of limited size, brexanolone demonstrated tolerability among SRSE patients of heterogeneous etiologies and was associated with a high rate of successful TLA weaning. The results suggest the possible development of brexanolone as an adjunctive therapy for SRSE requiring pharmacological coma for seizure control. Ann Neurol 2017;82:342-352.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
open label
stem cells
mechanical ventilation
clinical trial
randomized controlled trial
mesenchymal stem cells
study protocol
extracorporeal membrane oxygenation
patient reported